Agios Pharmaceuticals, Inc. $AGIO Shares Purchased by Boothbay Fund Management LLC

Key Points

• Boothbay Fund Management LLC increased its holdings in Agios Pharmaceuticals by 3.8%, owning approximately 261,221 shares valued at $7.65 million as of the end of the first quarter.
• Multiple large investors have also made substantial changes to their positions in Agios Pharmaceuticals, with Adage Capital Partners GP L.L.C. growing its stake by 145.2%.
• Agios Pharmaceuticals recently reported a loss of ($1.93) EPS for the last quarter, missing analysts' expectations, despite achieving a revenue of $12.50 million.

Boothbay Fund Management LLC increased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 261,221 shares of the biopharmaceutical company's stock after purchasing an additional 9,447 shares during the period. Boothbay Fund Management LLC owned 0.45% of Agios Pharmaceuticals worth $7,654,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of AGIO. Jefferies Financial Group Inc. purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at $49,290,000. Adage Capital Partners GP L.L.C. raised its stake in Agios Pharmaceuticals by 145.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company's stock worth $21,770,000 after acquiring an additional 440,000 shares during the last quarter. Palo Alto Investors LP acquired a new stake in Agios Pharmaceuticals during the 1st quarter worth about $8,104,000. Paradigm Biocapital Advisors LP purchased a new stake in Agios Pharmaceuticals during the 4th quarter valued at about $9,084,000. Finally, Deutsche Bank AG grew its stake in Agios Pharmaceuticals by 39.7% during the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after purchasing an additional 265,637 shares during the last quarter.

Agios Pharmaceuticals Price Performance

AGIO stock traded up $0.03 during trading on Tuesday, hitting $36.44. 169,511 shares of the company traded hands, compared to its average volume of 720,036. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The company has a market cap of $2.12 billion, a PE ratio of 3.32 and a beta of 0.87. The stock's 50-day simple moving average is $37.65 and its 200 day simple moving average is $33.21.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on AGIO shares. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank reduced their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research report on Monday, July 28th. Bank of America decreased their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $56.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $56.00.

Insider Activity at Agios Pharmaceuticals

In other news, Director David Scadden sold 1,400 shares of the firm's stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $40.00, for a total transaction of $56,000.00. Following the sale, the director directly owned 17,603 shares in the company, valued at $704,120. This trade represents a 7.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Cecilia Jones sold 1,780 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the completion of the transaction, the chief financial officer owned 30,049 shares of the company's stock, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,448 shares of company stock valued at $2,026,141 in the last quarter. 4.30% of the stock is currently owned by insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.